Skip to main content

Table 1 NRIP expression in 48 cores of tumors in US Biomax BCN962 tissue microarray

From: Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization

ID

Organ type

Histological diagnosis

Differentiation

IHC score/NRIP expression

A

Esophagus

   
 

A1-3

Squamous cell carcinoma

Poorly

6/+, 8/++, 0/-

B

Stomach

   
 

B1

Adenocarcinoma

Moderately

0/-

 

B2

x

 

0/-

 

B3

Mucinous Adenocarcinoma

Poorly

0/-

C

Colon

   
 

C1-2

Mucinous Adenocarcinoma

Moderately

6/+, 4/+

 

C3

x

 

0/-

D

Prostate

   
 

D1-2

Adenocarcinoma

Gleason's grade 3+4

0/-, 0/-

 

D3

Adenocarcinoma

Gleason's grade 4+5

0/-

E

Liver

   
 

E1-2

Hepatocellular carcinoma

Grade II

0/-, 0/-

 

E3

Hepatocellular carcinoma

Grade III

0/-

F

Lung

   
 

F1-2

Adenocarcinoma

Moderately

0/-, 0/-

 

F3

Squamous cell carcinoma

Moderately

0/-

G

Kidney

   
 

G1-2

Renal cell carcinoma

Conventional type

0/-, 0/-

 

G3

Nephroblastoma

 

0/-

H

Breast

   
 

H1-3

Infiltrating ductal carcinoma

Grade II

6/+, 0/-, 0/-

I

Uterine cervix

   
 

I1-3

Squamous cell carcinoma (Keratinized)

Moderately

0/-, 1/-, 0/-

J

Ovary

   
 

J1-3

Serous Adenocarcinoma

Grade III

9/++, 12/+++, 0/-

K

Urinary Bladder

   
 

K1, K3

Transitional cell carcinoma

Grade II

0/-, 0/-

 

K2

Transitional cell carcinoma

Grade III

0/-

L

Lymph node

   
 

L1-3

Large B-cell lymphoma

 

1/-, 2/-, 0/-

M

Skin

   
 

M1-2

Squamous cell carcinoma

Well

1/-, 0/-

 

M3

Squamous cell carcinoma

Poorly

4/+

N

Pancrease

   
 

N1, N3

Ductal Adenocarcinoma

Poorly

4/+, 0/-

 

N2

Acinar cell carcinoma

 

9/++

O

Testis

   
 

O1-2

Seminoma

 

0/-, 0/-

 

O3-4

x

 

0/-, 0/-

 

O5

Embryonal rhabdomyosarcoma

 

0/-

P

Tongue

   
 

P1

Alveolar rhabdomyosarcoma

 

0/-

  1. 1. IHC scores/NRIP expression: 10–12/+++ (Strong), 7–9/++ (intermediate), 3–6/+ (weak), 0–2/- (negative or low expression not exceed the cut-off threshold of 3).
  2. 2. x: tumor-sparing normal tissues